AUD24.67
1.12% today
Australia, Dec 30, 06:10 am CET
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Telix Pharmaceuticals Target price 2024 - Analyst rating & recommendation

Telix Pharmaceuticals Classifications & Recommendation:

Buy
75%
Hold
13%
Sell
13%

Telix Pharmaceuticals Price Target

Target Price AUD26.58
Price AUD24.67
Potential
Number of Estimates 6
6 Analysts have issued a price target Telix Pharmaceuticals 2025 . The average Telix Pharmaceuticals target price is AUD26.58. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 6 Analysts recommend Telix Pharmaceuticals to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Telix Pharmaceuticals stock has an average upside potential 2025 of . Most analysts recommend the Telix Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million AUD 502.55 770.88
213.90% 53.39%
EBITDA Margin 11.63% 15.26%
127.46% 31.23%
Net Margin 1.33% 6.34%
101.87% 376.64%

7 Analysts have issued a sales forecast Telix Pharmaceuticals 2024 . The average Telix Pharmaceuticals sales estimate is

AUD771m
Unlock
. This is
19.39% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
AUD787m 21.96%
Unlock
, the lowest is
AUD755m 16.90%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 AUD503m 213.90%
2024
AUD771m 53.39%
Unlock
2025
AUD1.0b 31.13%
Unlock
2026
AUD1.4b 37.93%
Unlock
2027
AUD1.6b 12.85%
Unlock

5 Analysts have issued an Telix Pharmaceuticals EBITDA forecast 2024. The average Telix Pharmaceuticals EBITDA estimate is

AUD118m
Unlock
. This is
63.04% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
AUD129m 79.06%
Unlock
, the lowest is
AUD107m 48.12%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 AUD58.4m 186.19%
2024
AUD118m 101.34%
Unlock
2025
AUD152m 28.94%
Unlock
2026
AUD316m 108.48%
Unlock

EBITDA Margin

2023 11.63% 127.46%
2024
15.26% 31.23%
Unlock
2025
15.01% 1.64%
Unlock
2026
22.68% 51.10%
Unlock

4 Telix Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Telix Pharmaceuticals net profit estimate is

AUD48.9m
Unlock
. This is
2.52% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
AUD78.5m 56.66%
Unlock
, the lowest is
AUD-13.4m 126.67%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 AUD6.7m 105.88%
2024
AUD48.9m 631.08%
Unlock
2025
AUD58.3m 19.28%
Unlock
2026
AUD176m 201.37%
Unlock

Net Margin

2023 1.33% 101.87%
2024
6.34% 376.64%
Unlock
2025
5.77% 8.99%
Unlock
2026
12.60% 118.37%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share AUD 0.02 0.15
105.88% 650.00%
P/E 170.62
EV/Sales 10.71

4 Analysts have issued a Telix Pharmaceuticals forecast for earnings per share. The average Telix Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

AUD0.15
Unlock
. This is
0.00% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
AUD0.24 60.00%
Unlock
, the lowest is
AUD-0.04 126.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 AUD0.02 105.88%
2024
AUD0.15 650.00%
Unlock
2025
AUD0.17 13.33%
Unlock
2026
AUD0.53 211.76%
Unlock

P/E ratio

Current 165.45 361.25%
2024
170.62 3.12%
Unlock
2025
143.06 16.15%
Unlock
2026
47.47 66.82%
Unlock

Based on analysts' sales estimates for 2024, the Telix Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

10.71
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
10.83
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 12.78 54.35%
2024
10.71 16.21%
Unlock
2025
8.17 23.74%
Unlock
2026
5.92 27.50%
Unlock
2027
5.25 11.39%
Unlock

P/S ratio

Current 12.93 50.23%
2024
10.83 16.24%
Unlock
2025
8.26 23.74%
Unlock
2026
5.99 27.50%
Unlock
2027
5.31 11.39%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today